In last trading session, Trevi Therapeutics Inc (NASDAQ:TRVI) saw 1.13 million shares changing hands with its beta currently measuring 0.94. Company’s recent per share price level of $4.15 trading at -$0.35 or -7.78% at ring of the bell on the day assigns it a market valuation of $319.00M. That closing price of TRVI’s stock is at a discount of -10.84% from its 52-week high price of $4.60 and is indicating a premium of 69.64% from its 52-week low price of $1.26. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 7.77 million shares which gives us an average trading volume of 1.64 million if we extend that period to 3-months.
For Trevi Therapeutics Inc (TRVI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.10. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.12 in the current quarter.
Trevi Therapeutics Inc (NASDAQ:TRVI) trade information
Upright in the red during last session for losing -7.78%, in the last five days TRVI remained trading in the green while hitting it’s week-highest on Wednesday, 12/18/24 when the stock touched $4.15 price level, adding 11.32% to its value on the day. Trevi Therapeutics Inc’s shares saw a change of 209.70% in year-to-date performance and have moved 66.67% in past 5-day. Trevi Therapeutics Inc (NASDAQ:TRVI) showed a performance of 47.16% in past 30-days. Number of shares sold short was 1.41 million shares which calculate 2.76 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 30.83% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -44.58% in reaching the projected high whereas dropping to the targeted low would mean a loss of -44.58% for stock’s current value.
Trevi Therapeutics Inc (TRVI) estimates and forecasts
Statistics highlight that Trevi Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 57.20% of value to its shares in past 6 months, showing an annual growth rate of -68.97% while that of industry is 17.30. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 27.24% during past 5 years.
Trevi Therapeutics Inc (NASDAQ:TRVI)’s Major holders
Insiders are in possession of 1.03% of company’s total shares while institution are holding 70.43 percent of that, with stock having share float percentage of 71.16%. Investors also watch the number of corporate investors in a company very closely, which is 70.43% institutions for Trevi Therapeutics Inc that are currently holding shares of the company. NEA MANAGEMENT COMPANY, LLC is the top institutional holder at TRVI for having 11.37 million shares of worth $33.88 million. And as of 2024-06-30, it was holding 11.4255 of the company’s outstanding shares.
The second largest institutional holder is FRAZIER LIFE SCIENCES MANAGEMENT, L.P., which was holding about 7.38 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4169 of outstanding shares, having a total worth of $22.0 million.
